Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.33 |
| ▸ | CYP21A2 | P08686 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 2/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5999951 | 0.85 | USP2 (0.55) | RAB9AUSP2CYP17A1KIF11 | |
| SCHEMBL6000236 | 0.85 | KCNN4 (0.40) | RAB9AUSP2CYP17A1CYP11B1KIF11 | |
| SCHEMBL5999956 | 0.82 | CYP19A1 (0.37) | CYP11B1KIF11 | |
| SCHEMBL6000325 | 0.79 | CYP17A1 (0.39) | RAB9AUSP2CYP17A1CYP11B1KIF11 | |
| SCHEMBL5999962 | 0.79 | CYP19A1 (0.39) | KIF11 | |
| SCHEMBL5999709 | 0.77 | KIF11 (0.49) | KIF11 | |
| SCHEMBL5999948 | 0.76 | TSHR (0.38) | RAB9AUSP2KIF11 | |
| SCHEMBL6000436 | 0.74 | LMNA (0.37) | RAB9AUSP2KIF11 | |
| SCHEMBL5999689 | 0.74 | CYP19A1 (0.55) | — | |
| SCHEMBL6000278 | 0.72 | MAPK14 (0.40) | RAB9AKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | RAB9A 3582/4885USP2 3011/4885CYP17A1 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.